Aladdin Healthcare Technologies SE (ALDNF) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aladdin Healthcare Technologies SE (ALDNF) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Bewertet mit 44/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 18. März 2026Aladdin Healthcare Technologies SE (ALDNF) Gesundheitswesen & Pipeline-Uebersicht
Aladdin Healthcare Technologies SE, based in Germany, develops AI and blockchain-based healthcare solutions, including platforms for early disease diagnosis, risk assessment, and drug discovery. Operating in the healthcare information services sector, the company targets chronic diseases using advanced predictive data analytics.
Investmentthese
Aladdin Healthcare Technologies SE presents a speculative investment opportunity within the healthcare information services sector. The company's focus on AI and blockchain technologies for early disease diagnosis and drug discovery could drive future growth, although the company's small size and OTC listing present significant risks. Key value drivers include successful development and commercialization of its AI-powered platforms, particularly the Early Diagnosis and Drug Discovery platforms. Upcoming catalysts include potential partnerships with healthcare providers and pharmaceutical companies to deploy its technologies. However, investors should be aware of the risks associated with OTC-listed companies, including limited liquidity and disclosure.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Aladdin Healthcare Technologies SE operates in the healthcare information services sector, focusing on AI and blockchain technologies.
- The company's P/E ratio is -0.22, reflecting its current lack of profitability.
- Aladdin Healthcare Technologies SE has a beta of 0.55, indicating lower volatility compared to the market.
- The company develops AI-powered platforms for early disease diagnosis, health risk assessment, and drug discovery.
- Aladdin Healthcare Technologies SE employs 3 people, reflecting its small scale of operations.
Wettbewerber & Vergleichsunternehmen
Staerken
- Innovative AI-powered platforms for early disease diagnosis.
- Secure data management using blockchain technology.
- Focus on addressing chronic diseases with high prevalence.
- Potential for partnerships with healthcare providers and pharmaceutical companies.
Schwaechen
- Small company size and limited resources.
- Dependence on successful development and commercialization of new technologies.
- Limited operating history and track record.
- OTC listing with associated liquidity and disclosure risks.
Katalysatoren
- Upcoming: Potential partnerships with healthcare providers to implement AI diagnostic platforms.
- Upcoming: Development and launch of new AI-powered healthcare solutions.
- Ongoing: Continued research and development in AI-assisted drug discovery.
- Ongoing: Expansion of blockchain technology for secure data management.
Risiken
- Potential: Intense competition from larger healthcare technology companies.
- Potential: Regulatory hurdles and compliance requirements in the healthcare industry.
- Potential: Data security and privacy concerns related to patient information.
- Ongoing: Limited liquidity and high volatility due to OTC listing.
Wachstumschancen
- Expansion of AI-Powered Diagnostic Platforms: Aladdin Healthcare Technologies SE has the opportunity to expand its AI-powered diagnostic platforms for early disease detection. The global AI in healthcare market is projected to reach $95 billion by 2030, offering a substantial market for Aladdin's AI Early Diagnosis platform. Successful development and deployment of these platforms could drive significant revenue growth.
- Strategic Partnerships with Healthcare Providers: Forming strategic partnerships with hospitals, clinics, and other healthcare providers can accelerate the adoption of Aladdin's technologies. These partnerships can provide access to larger patient populations and facilitate the integration of Aladdin's platforms into existing healthcare workflows. Successful partnerships could lead to recurring revenue streams and increased market penetration.
- Drug Discovery Platform Commercialization: Aladdin's AI-assisted Drug Discovery platform presents a significant growth opportunity. The global drug discovery market is expected to reach $81.3 billion by 2028. By identifying promising drug candidates for age-related diseases, Aladdin can generate revenue through licensing agreements or the development of its own drug pipeline.
- Geographic Expansion into New Markets: Aladdin Healthcare Technologies SE can expand its operations into new geographic markets, particularly in regions with growing healthcare expenditures and increasing adoption of digital health technologies. Emerging markets in Asia and Latin America offer significant growth potential for Aladdin's AI and blockchain-based solutions. Expansion into these markets can diversify revenue streams and reduce reliance on the European market.
- Integration of Blockchain for Data Security: Leveraging blockchain technology to enhance data security and privacy can attract healthcare providers and patients concerned about data breaches and regulatory compliance. The blockchain in healthcare market is projected to reach $1.6 billion by 2027. By offering secure and transparent data management solutions, Aladdin can differentiate itself from competitors and gain a competitive advantage.
Chancen
- Expanding into new geographic markets with growing healthcare expenditures.
- Forming strategic alliances with hospitals and research institutions.
- Leveraging AI and machine learning to enhance drug discovery.
- Capitalizing on the increasing adoption of digital health solutions.
Risiken
- Intense competition from larger and more established healthcare technology companies.
- Regulatory hurdles and compliance requirements in the healthcare industry.
- Data security and privacy concerns related to patient information.
- Potential for technological obsolescence and disruption.
Wettbewerbsvorteile
- Proprietary AI algorithms for early disease diagnosis.
- Blockchain technology for secure and transparent data management.
- Expertise in healthcare data analytics and machine learning.
- Strategic partnerships with healthcare providers and research institutions.
Ueber ALDNF
Founded in 2014 and headquartered in Berlin, Germany, Aladdin Healthcare Technologies SE operates through its subsidiary, Aladdin Healthcare Technologies Ltd, focusing on the intersection of healthcare and advanced technology. The company develops software solutions for health information storage and management, leveraging blockchain technology to ensure data security and integrity. Aladdin specializes in technologies such as blockchain, machine learning, and artificial intelligence to create innovative healthcare platforms. Its core offerings include the Artificial Intelligence Early Diagnosis platform, designed for brain imaging analysis, the Health Risk Assessment platform, which assesses the risk of cardiovascular, diabetes, and kidney-related diseases, and the Artificial Intelligence assisted Drug Discovery platform, aimed at identifying small molecule drug compounds for age-related diseases like Alzheimer's, Parkinson's, and SARS-CoV-2. By using blockchain, machine learning, AI, and advanced predictive data analytics, Aladdin aims to facilitate the early diagnosis of chronic diseases, improving patient outcomes and reducing healthcare costs. The company's focus on AI and blockchain positions it as a player in the evolving landscape of healthcare technology.
Was das Unternehmen tut
- Develops software solutions for health information storage and management.
- Utilizes blockchain technology for secure data handling.
- Specializes in artificial intelligence and machine learning applications in healthcare.
- Creates AI-powered platforms for early disease diagnosis.
- Offers health risk assessment tools for cardiovascular, diabetes, and kidney-related diseases.
- Develops AI-assisted drug discovery platforms for age-related diseases.
Geschaeftsmodell
- Develops and licenses AI-powered healthcare platforms to hospitals and clinics.
- Generates revenue through software subscriptions and licensing fees.
- Partners with pharmaceutical companies for drug discovery and development.
- Provides data analytics services to healthcare providers.
Branchenkontext
Aladdin Healthcare Technologies SE operates within the healthcare information services industry, a sector experiencing rapid growth due to the increasing adoption of digital health solutions and the need for efficient data management. The market is driven by factors such as the rising prevalence of chronic diseases, the growing demand for personalized medicine, and advancements in AI and machine learning. Competitors include companies like Applied Therapeutics Inc (APTCF), and MedMira Inc (MMNFF). Aladdin's focus on blockchain and AI differentiates it within this competitive landscape.
Wichtige Kunden
- Hospitals and clinics seeking to improve diagnostic accuracy and efficiency.
- Pharmaceutical companies looking for AI-driven drug discovery solutions.
- Healthcare providers aiming to enhance patient risk assessment and management.
- Research institutions interested in AI-based healthcare data analysis.
Finanzdaten
Chart & Info
Aladdin Healthcare Technologies SE (ALDNF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer ALDNF verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer ALDNF.
Kursziele
Wall-Street-Kurszielanalyse fuer ALDNF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von ALDNF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Wade Menpes-Smith
Managing Director
Wade Menpes-Smith serves as the Managing Director of Aladdin Healthcare Technologies SE. His background includes experience in managing small teams and overseeing the development of technology solutions. His leadership is focused on driving the company's strategic initiatives in AI and blockchain-based healthcare solutions. He is responsible for guiding the company's research and development efforts and fostering partnerships with healthcare providers and pharmaceutical companies.
Erfolgsbilanz: Under Wade Menpes-Smith's leadership, Aladdin Healthcare Technologies SE has focused on developing its AI-powered platforms for early disease diagnosis and drug discovery. He has overseen the company's efforts to leverage blockchain technology for secure data management and has worked to establish partnerships to expand the reach of Aladdin's solutions. Given the company's small size, his role is critical in shaping its strategic direction.
ALDNF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Aladdin Healthcare Technologies SE may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries higher risks due to the lack of regulatory oversight and potential for fraud or manipulation compared to stocks listed on major exchanges like the NYSE or NASDAQ.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited liquidity due to OTC Other listing.
- Lack of regulatory oversight and potential for fraud or manipulation.
- Inconsistent or limited financial reporting.
- High price volatility and potential for significant losses.
- Dependence on successful development and commercialization of new technologies.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's competitive position and market opportunities.
- Evaluate the company's technology and intellectual property.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Focus on AI and blockchain technologies in healthcare.
- Development of AI-powered platforms for early disease diagnosis.
- Partnerships with healthcare providers and research institutions (if any).
- Presence of a management team with relevant experience.
Aladdin Healthcare Technologies SE Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for ALDNF?
Aladdin Healthcare Technologies SE (ALDNF) currently holds an AI score of 44/100, indicating low score. Key strength: Innovative AI-powered platforms for early disease diagnosis.. Primary risk to monitor: Potential: Intense competition from larger healthcare technology companies.. This is not financial advice.
How frequently does ALDNF data refresh on this page?
ALDNF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ALDNF's recent stock price performance?
Recent price movement in Aladdin Healthcare Technologies SE (ALDNF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative AI-powered platforms for early disease diagnosis.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ALDNF overvalued or undervalued right now?
Determining whether Aladdin Healthcare Technologies SE (ALDNF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ALDNF?
Before investing in Aladdin Healthcare Technologies SE (ALDNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ALDNF to a portfolio?
Potential reasons to consider Aladdin Healthcare Technologies SE (ALDNF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Innovative AI-powered platforms for early disease diagnosis.. Additionally: Secure data management using blockchain technology.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of ALDNF?
Yes, most major brokerages offer fractional shares of Aladdin Healthcare Technologies SE (ALDNF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ALDNF's earnings and financial reports?
Aladdin Healthcare Technologies SE (ALDNF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for ALDNF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on publicly available sources and may be limited due to the company's OTC listing and limited disclosure.